Nationals and residents of the People’s Republic of China will continue to have the option to select the EPO as their International Searching Authority (ISA) for international patent applications filed in English under the Patent Cooperation Treaty (PCT) until 30 November 2026. This follows the success of the pilot scheme first started in December 2020, which is being extended for a further three years as mutually agreed between the European Patent Office (EPO) and the China National Intellectual Property Administration (CNIPA).
This extension enables nationals and residents of the People’s Republic of China to continue to obtain international searches and written opinions from the EPO, supporting their strategic objectives when considering patent protection in Europe. By using the EPO as their ISA, applicants can speed up the European patent grant process and save even more prosecution time if they request early entry into the European phase. Furthermore, they can save costs as neither a supplementary European search nor a translation of the PCT application would be required and the examination fee payable on entry into the European phase would be reduced by 75% when requesting international preliminary examination under PCT Chapter II with the EPO.
The decision to extend the scheme follows the pilot’s favourable evaluation by applicants, including enterprises, universities, research institutes, and private individuals. The capacity of the pilot remains set at 3 000 applications per year.
Dear colleagues, we would like to inform you about the weekends and holidays in 2025…
Maria Nilova and Nikolai Kovkov from Patentica recently participated in the AIPLA 2024 Annual Meeting…
Maria Nilova and Nikolai Kovkov from Patentica recently took part in the LES USA-Canada Annual…
On October 9, a meeting of the Advisory Committee on Intellectual Property under the Board…
The Russian Patent and Trademark Office has issued clarifications regarding some typical questions on the…
Patentica’s patent attorneys, Victor Lisovenko and Ksenia Emelianova have successfully represented Sun Pharmaceuticals in opposing…